title: Debromination of (alpha-bromoiso-valeryl)urea catalysed by rat blood.
abstract: (Alpha-bromoiso-valeryl) urea, a sedative or hypnotic, is metabolized to (3-methylbutyryl)urea by reductive debromination. This study was designed to evaluate the role of blood in the debromination of (alpha-bromoiso-valeryl) urea. Rat blood containing an electron donor had significant debrominating activity toward (alpha-bromoiso-valeryl)urea. This debromination proceeded by enzymatic and non-enzymatic processes which required both NADH (or NADPH) and flavin mononucleotide (FMN), under anaerobic conditions. The debrominating activity was sensitive to inhibition by carbon monoxide, and the pH optimum was 8.5. When FMN was replaced by flavin adenine dinucleotide (FAD) or riboflavin, similar results were obtained. The optimum concentration of flavins was 10(-4) M. The reductive debromination was also mediated by rat erythrocytes, but not by plasma. When the blood or erythrocytes were boiled, the debrominating activity was not abolished, but was enhanced, suggesting that the activity arises from the haemoglobin in erythrocytes, and haemoglobin had debrominating activity when supplemented with both a reduced pyridine nucleotide and a flavin. Furthermore, haematin had significant debrominating activity in the presence of these cofactors. The activity of haematin was also observed with the photochemically reduced form of FMN. The results imply that the debromination proceeds in two steps--enzymatic or non-enzymatic reduction of a flavin such as FAD, FMN or riboflavin by NADPH or NADH, then non-enzymatic reductive debromination of (alpha-bromoiso-valeryl)urea to (3-methylbutyryl)urea catalysed by the haem group of rat haemoglobin in the presence of the reduced flavin.
authors: Institute of Pharmaceutical Science, Hiroshima University School of Medicine, Japan.
authors: S
authors: S
authors: Kitamura
authors: M
authors: M
authors: Kuwasako
authors: K
authors: K
authors: Sugihara
authors: K
authors: K
authors: Tatsumi
authors: S
authors: S
authors: Ohta
mesh_terms: D000818:Animals; D001769:Blood / Q000378:metabolism*; D001798:Blood Proteins / Q000032:analysis; D004305:Dose-Response Relationship, Drug; D004798:Enzymes / Q000097:blood*; D005486:Flavin Mononucleotide / Q000378:metabolism; D005182:Flavin-Adenine Dinucleotide / Q000378:metabolism; D006427:Hemin / Q000032:analysis / Q000378:metabolism; D006454:Hemoglobins / Q000378:metabolism; D006358:Hot Temperature; D006863:Hydrogen-Ion Concentration; D006993:Hypnotics and Sedatives / Q000378:metabolism*; D066298:In Vitro Techniques; D008297:Male; D009243:NAD / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D012256:Riboflavin / Q000378:metabolism*; D013997:Time Factors; D014508:Urea / Q000031:analogs & derivatives* / Q000378:metabolism
chemical_list: C119881:(3-methylbutyryl)urea; C119882:(bromoiso-valeryl)urea; D001798:Blood Proteins; D004798:Enzymes; D006454:Hemoglobins; D006993:Hypnotics and Sedatives; D009243:NAD; D005182:Flavin-Adenine Dinucleotide; D006427:Hemin; D005486:Flavin Mononucleotide; D014508:Urea; D012256:Riboflavin